- Home
- TLPH vs SRTS Comparison
TLPH vs SRTS Comparison
Compare TLPH & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLPH | SRTS |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.3M | 44.3M |
| IPO Year | 2010 | 2016 |
Fundamental Metrics
Financial Performance| Metric | TLPH | SRTS |
|---|---|---|
| Price | $1.30 | $2.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 442.1K | 21.8K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,151,000.00 | ★ $27,482,000.00 |
| Revenue This Year | N/A | $2.00 |
| Revenue Next Year | N/A | $34.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.39 | $2.66 |
| 52 Week High | $1.57 | $5.92 |
Technical Indicators
Market Signals| Indicator | TLPH | SRTS |
|---|---|---|
| Relative Strength Index (RSI) | 55.96 | 45.24 |
| Support Level | $1.01 | $2.87 |
| Resistance Level | $1.46 | $3.28 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 26.32 | 9.52 |
Price Performance
Historical ComparisonAbout TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.